INTRODUCTION: Large deletions of the NF1 gene and its flanking regions are frequently associated with a severe clinical manifestation. Different types of gross NF1 deletion have been identified that are distinguishable both by their size and the number of genes included within the deleted regions. Type-1 NF1 deletions encompass 1.4 Mb and include 14 genes, whereas the much less common type-2 NF1 deletions span 1.2 Mb and contain 13 genes. Genotype-phenotype correlations in patients with large NF1 deletions are likely to be influenced by the nature and number of the genes deleted in addition to the NF1 gene. Whereas the clinical phenotype associated with type-1 NF1 deletions has been well documented, the detailed clinical characterization of patients with non-mosaic type-2 NF1 deletions has not so far been reported. CASE PRESENTATION: In the present report we characterized two Caucasian European patients with non-mosaic (germline) type-2 NF1 deletions. Our first patient was a 13-year-old girl with dysmorphic facial features, mild developmental delay, large hands and feet, hyperflexibility of the joints, macrocephaly and T2 hyperintensities in the brain. A whole-body magnetic resonance imaging scan indicated two internal plexiform neurofibromas. Our second patient was an 18-year-old man who exhibited dysmorphic facial features, developmental delay, learning disability, large hands and feet, hyperflexibility of the joints, macrocephaly and a very high subcutaneous and internal tumor load as measured volumetrically on whole-body magnetic resonance imaging scans. At the age of 18 years, he developed a malignant peripheral nerve sheath tumor and died from secondary complications. Both our patients exhibited cardiovascular malformations. CONCLUSIONS: Our two patients with non-mosaic type-2 NF1 deletions exhibited clinical features that have been reported in individuals with germline type-1 NF1 deletions. Therefore, a severe disease manifestation is not confined to only patients with type-1 NF1 deletions but may also occur in individuals with type-2 NF1 deletions. Our findings support the concept of an NF1 microdeletion syndrome with severe clinical manifestation that is caused by type-1 as well as type-2 NF1 deletions.
INTRODUCTION: Large deletions of the NF1 gene and its flanking regions are frequently associated with a severe clinical manifestation. Different types of gross NF1 deletion have been identified that are distinguishable both by their size and the number of genes included within the deleted regions. Type-1 NF1 deletions encompass 1.4 Mb and include 14 genes, whereas the much less common type-2 NF1 deletions span 1.2 Mb and contain 13 genes. Genotype-phenotype correlations in patients with large NF1 deletions are likely to be influenced by the nature and number of the genes deleted in addition to the NF1 gene. Whereas the clinical phenotype associated with type-1 NF1 deletions has been well documented, the detailed clinical characterization of patients with non-mosaic type-2 NF1 deletions has not so far been reported. CASE PRESENTATION: In the present report we characterized two Caucasian European patients with non-mosaic (germline) type-2 NF1 deletions. Our first patient was a 13-year-old girl with dysmorphic facial features, mild developmental delay, large hands and feet, hyperflexibility of the joints, macrocephaly and T2 hyperintensities in the brain. A whole-body magnetic resonance imaging scan indicated two internal plexiform neurofibromas. Our second patient was an 18-year-old man who exhibited dysmorphic facial features, developmental delay, learning disability, large hands and feet, hyperflexibility of the joints, macrocephaly and a very high subcutaneous and internal tumor load as measured volumetrically on whole-body magnetic resonance imaging scans. At the age of 18 years, he developed a malignant peripheral nerve sheath tumor and died from secondary complications. Both our patients exhibited cardiovascular malformations. CONCLUSIONS: Our two patients with non-mosaic type-2 NF1 deletions exhibited clinical features that have been reported in individuals with germline type-1 NF1 deletions. Therefore, a severe disease manifestation is not confined to only patients with type-1 NF1 deletions but may also occur in individuals with type-2 NF1 deletions. Our findings support the concept of an NF1 microdeletion syndrome with severe clinical manifestation that is caused by type-1 as well as type-2 NF1 deletions.
Authors: M Venturin; P Guarnieri; F Natacci; M Stabile; R Tenconi; M Clementi; C Hernandez; P Thompson; M Upadhyaya; L Larizza; P Riva Journal: J Med Genet Date: 2004-01 Impact factor: 6.318
Authors: E Petek; D E Jenne; J Smolle; B Binder; W Lasinger; C Windpassinger; K Wagner; P M Kroisel; H Kehrer-Sawatzki Journal: J Med Genet Date: 2003-07 Impact factor: 6.318
Authors: C López-Correa; M Dorschner; H Brems; C Lázaro; M Clementi; M Upadhyaya; D Dooijes; U Moog; H Kehrer-Sawatzki; J L Rutkowski; J P Fryns; P Marynen; K Stephens; E Legius Journal: Hum Mol Genet Date: 2001-06-15 Impact factor: 6.150
Authors: T De Raedt; H Brems; P Wolkenstein; D Vidaud; S Pilotti; F Perrone; V Mautner; S Frahm; R Sciot; E Legius Journal: Am J Hum Genet Date: 2003-03-26 Impact factor: 11.025
Authors: D Gareth R Evans; Catherine O'Hara; Anna Wilding; Sarah L Ingham; Elizabeth Howard; John Dawson; Anthony Moran; Vilka Scott-Kitching; Felicity Holt; Susan M Huson Journal: Eur J Hum Genet Date: 2011-06-22 Impact factor: 4.246
Authors: H Kehrer-Sawatzki; L Kluwe; C Sandig; M Kohn; K Wimmer; U Krammer; A Peyrl; D E Jenne; I Hansmann; V-F Mautner Journal: Am J Hum Genet Date: 2004-07-15 Impact factor: 11.025
Authors: K A Mensink; R P Ketterling; H C Flynn; R A Knudson; N M Lindor; B A Heese; R J Spinner; D Babovic-Vuksanovic Journal: J Med Genet Date: 2006-02 Impact factor: 6.318